Disc Medicine, Inc. (IRON) · Oct 19, 2026 · Other events

Disc Medicine Phase 3 trial clears endpoints, reviving FDA path

Above the bar — All co-primary and secondary endpoints met; PPIX -41.4% and light tolerance +12.2 hours vs placebo

Disc Medicine’s APOLLO Phase 3 trial met every primary and secondary endpoint, giving bitopertin a stronger route back to FDA review.

Disc Medicine is a clinical-stage hematology company whose lead asset, bitopertin, is being developed as a potential disease-modifying treatment for erythropoietic protoporphyria, while its other programs remain in mid-stage development. The APOLLO trial was already the expected route to address the FDA’s earlier Complete Response Letter, with topline data guided for the fourth quarter of 2026.

The pivotal trial delivered materially more than a bare pass. APOLLO met both co-primary endpoints and every secondary endpoint in 183 patients, turning the FDA response from a binary regulatory risk into a credible resubmission case. The filing says, “The trial met all its primary and secondary endpoints.” 〔0〕

The efficacy signal reaches both biology and lived disease burden. The result was not limited to lowering PPIX, the disease-related metabolite: patients also spent more time in light without pain, experienced fewer phototoxic reactions, and reported better quality-of-life scores. That breadth is important because the prior regulatory problem was not simply whether bitopertin affected its target; APOLLO needed to show clinically meaningful benefit. The filing reports, “Bitopertin achieved statistical significance on all secondary endpoints vs. placebo.”

Safety looks usable, but not frictionless. No new safety signal or treatment discontinuation emerged, and the filing says there were no adverse events above Grade 3. However, dizziness occurred in 50% of bitopertin-treated patients, versus 11% on placebo in the presentation’s safety table, so the eventual label and real-world tolerability profile still matter. The filing states, “dizziness was the most commonly reported treatment emergent adverse event (TEAE) in the bitopertin group (50%) and was mild or moderate and generally transient.” 〔1〕

The regulatory path advances, but approval is still the next test. Management plans to resubmit the NDA by the end of 2026 and anticipates an FDA decision by mid-2027. That timing was broadly expected after the CRL and prior APOLLO guidance, so the new information is primarily the strength and consistency of the readout—not the existence of a regulatory plan. Bitopertin remains investigational and is not yet approved.

Bottom line: APOLLO clears the trial’s success bar decisively, with efficacy across every major measure and no new safety signal. It materially strengthens Disc’s lead program and makes the NDA resubmission a substantive regulatory opportunity rather than a speculative rescue attempt, but FDA approval remains unresolved.

What to watch next

NDA resubmission by year-end 2026; FDA decision mid-2027

Original filing on SEC EDGAR

More Disc Medicine, Inc. news

• Disc Medicine earnings beat as bitopertin heads back to FDA
• Disc Medicine’s DISC-3405 cuts PV phlebotomy, but Phase 2 proof remains early